For patients receiving anticoagulation therapy for VTE who survive an episode of major bleeding, the ASH guideline panel suggests resumption of oral anticoagula- tion therapy within 90 days rather than discontinuation of oral anticoagulation therapy (conditional recommendation based on very low certainty in the evidence about effects ). Remark: This recommendation specifically applies to patients who require long-term or indefinite anticoagulation (ie, are at moderate to high risk for recurrent VTE, are not at high risk for recurrent bleeding, and are willing to continue anticoagulation therapy). Values and preferences In general, these recommendations place greater value on outcomes related to prevention of mortality, PE, deep vein thrombosis (DVT), major bleeding, quality of life, and emergency department and/or hospital visits. The impact of recommendations on measures of anticoagulation control, medication adherence, and inconvenience of therapy was also considered in relation to their importance for patients. Explanations and other considerations These recommendations take into consideration cost and cost- effectiveness, impact on equity, acceptability, and feasibility. Good practice statements: renal function monitoring For patients with creatinine clearance of $50 mL/min receiving DOAC therapy for treatment of VTE, the ASH guideline panel agrees that good practice includes renal function monitoring every 6 to 12 months (ungraded good practice statement). For patients with creatinine clearance of ,50 mL/min receiving DOAC therapy for treatment of VTE, the ASH guideline panel agrees that good practice includes renal function monitor- ing approximately every 3 months (ungraded good practice statement). Introduction Aim(s) of these guidelines and specific objectives The purpose of these guidelines is to provide evidence-based recommendations addressing the optimal use of anticoagulant therapy in the management of VTE assuming the choice of which anticoagulant to use has already been made. 